Bonus Biogroup Ltd (BONS)

Bonus Biogroup Balance Sheet

Financials in millions ILS. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	6.86	12.94
Short-Term Investments	-	13.04
Cash & Cash Equivalents	6.86	25.98
Cash Growth	-73.59%	-
Receivables	0.33	0.46
Total Current Assets	7.19	26.44
Property, Plant & Equipment	9.17	10.58
Goodwill and Intangibles	6.67	7.5
Other Long-Term Assets	0.38	0.37
Total Long-Term Assets	16.22	18.45
Total Assets	23.41	44.89
Accounts Payable	6.11	4.3
Current Debt	1.66	1.48
Other Current Liabilities	0.15	0.13
Total Current Liabilities	7.92	5.91
Long-Term Debt	8.53	9.67
Total Long-Term Liabilities	8.53	9.67
Total Liabilities	16.45	15.58
Total Debt	9.58	7.39
Debt Growth	29.50%	-
Retained Earnings	-337.6	-309.78
Shareholders' Equity	6.96	29.31
Net Cash / Debt	-2.72	18.58
Working Capital	-0.73	20.53

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).